Involvement of the Serotonergic System in the Control of Impulsivity in Tourette Disorder.

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer (\[18F\]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

⁃ Male or Female

• Diagnosed with a Tourette Disorder following the DSM-5

• Age between 18-65 years

• Member of a social security scheme in France

• Freely-given informed consent to participate to this study (written form)

• With a current treatment by aripiprazole already scheduled

• With Tics compatible with TEP/fMRI exams

• Having (for women only) effective contraception throughout participation in the study.

Locations
Other Locations
France
Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon
RECRUITING
Bron
Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière
NOT_YET_RECRUITING
Paris
Contact Information
Primary
Benjamin PASQUEREAU
benjamin.pasquereau@isc.cnrs.fr
+33 437 911 241
Backup
Stephane THOBOIS
stephane.thobois@chu-lyon.fr
+33 472 357 222
Time Frame
Start Date: 2024-09-24
Estimated Completion Date: 2028-09-24
Participants
Target number of participants: 25
Treatments
Experimental: Tourette disorder
25 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials